Provide an evidence‑based summary of acute myocardial infarction occurring on a healed infarct in a 25‑year‑old male due to accelerated premature coronary atherosclerosis, including epidemiology, pathophysiology, genetic causes (familial hypercholesterolemia, LDL‑receptor mutations, apolipoprotein B defects, PCSK9 gain‑of‑function variants, lipoprotein (a) elevation), plaque instability, differential diagnoses for myocardial infarction at age 25, and emerging diagnostic and early‑detection strategies (novel biomarkers, genetic screening, coronary artery calcium scoring, coronary CT angiography, cardiac magnetic resonance imaging, PET) with key landmark studies from the past 10‑15 years.

Myocardial Infarction in Very Young Adults: Evidence-Based Summary for Pathology Poster

Epidemiology of MI in Patients <30 Years

Myocardial infarction in patients under 30 years is rare but increasingly recognized, with familial hypercholesterolemia (FH) representing the most common monogenic cause of premature atherosclerotic coronary artery disease in this age group. 1

• FH affects approximately 1 in 311 individuals in the general population, potentially impacting up to 35 million people worldwide, yet only 10% of cases are currently diagnosed 1
• Among patients with premature myocardial infarction (defined as <55 years in men, <65 years in women), the prevalence of genetically confirmed FH ranges from 4.4% to 7.6% in recent cohort studies 2, 3
• The proportion of young individuals presenting with acute MI has increased in recent years, with smoking observed in 25.5% of premature CAD patients versus 12.2% of non-premature CAD patients 4, 5
• By age 50, untreated FH results in clinical cardiovascular disease in 50% of men and 25% of women, with ischemic heart disease occurring in 1 in 6 men and 1 in 10 women by age 40 1

Mechanisms of Premature Atherosclerosis

Lifetime exposure to markedly elevated LDL-cholesterol from birth drives accelerated atherosclerosis in young FH patients, with every 10-15 mg/dL increase in non-HDL cholesterol corresponding to an additional year of vascular aging. 1

Pathophysiological Cascade

• FH results from defects in the hepatic LDL clearance pathway, leading to impaired clearance of circulating LDL particles and markedly elevated LDL-cholesterol concentrations from birth 1
• The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) and Bogalusa Heart Study demonstrated that a 15-year-old with heterozygous FH has the same atherosclerotic burden as a 20-35 year old with average lipid profile 1
• Elevated Lp(a) exerts proatherogenic, proinflammatory, and potentially prothrombotic properties that synergistically accelerate atherosclerosis beyond LDL-cholesterol effects alone 6
• Conventional risk calculators significantly underestimate cardiovascular risk in FH patients due to lifetime cumulative LDL exposure not captured by standard models 7

Genetic Causes of Premature Atherosclerosis

LDLR Mutations (Most Common)

• LDLR gene mutations represent the most frequent cause of FH, resulting in varying degrees of LDL receptor dysfunction depending on the specific mutation 1, 8
• Loss-of-function mutations in LDLR are heterozygous in most cases, with homozygous FH being rare but associated with extreme LDL-cholesterol elevation and childhood-onset cardiovascular disease 1
• Novel LDLR mutations continue to be discovered in premature MI cohorts, including LDLR c.129G>C and LDLR c.1867A>T identified in recent Chinese studies 2

APOB Mutations (Familial Defective ApoB-100)

• APOB mutations cause Familial Defective Apolipoprotein B-100, representing a milder form of monogenic hypercholesterolemia compared to classic LDLR mutations, though premature coronary disease still develops 8
• These mutations impair the binding of apolipoprotein B-100 to the LDL receptor, reducing hepatic LDL clearance 1

PCSK9 Gain-of-Function Mutations

• Gain-of-function mutations in PCSK9 enhance degradation of LDL receptors, reducing hepatic LDL clearance and elevating circulating LDL-cholesterol 1
• Conversely, Mendelian randomization studies demonstrate that loss-of-function PCSK9 mutations associate with reduced LDL-cholesterol and substantial reductions in coronary heart disease risk 1
• Genetic variants at the PCSK9 locus that specifically associate with LDL-cholesterol also predict coronary heart disease risk 1

LDLRAP1 Mutations (Autosomal Recessive Hypercholesterolemia)

• LDLRAP1 mutations cause autosomal recessive hypercholesterolemia, a rare form of FH 1
• Novel LDLRAP1 mutations (c.65G>C and c.274G>A) have been identified in premature MI cohorts 2

Lipoprotein(a) Elevation

Elevated Lp(a) is a heritable, independent, and causal risk factor for ASCVD that persists even when LDL-cholesterol is at guideline-recommended targets. 6, 9

• Lp(a) is composed of an LDL-like particle and characteristic apolipoprotein(a) connected by a disulfide bond, with levels primarily genetically determined 6
• Current guidelines recommend Lp(a) measurement for patients with familial hypercholesterolemia, family history of early ASCVD or elevated Lp(a), and progressive ASCVD despite optimal therapy 6
• Elevated Lp(a) levels (typically >50 mg/dL or >125 nmol/L) serve as risk modifiers in the 2025 ESC guidelines, reclassifying patients to higher risk categories 10
• Patients with elevated Lp(a) treated with PCSK9 inhibitors may have greater ASCVD risk reduction and should be prioritized for therapy until direct Lp(a)-lowering agents become available 11, 9

Polygenic Contributions

• Clinical overreliance on monogenic genes can result in overlooked genetic causes of premature CAD, especially polygenic contributions that account for substantial FH-like phenotypes 4
• Polygenic scores for hypercholesterolemia are not yet fully standardized and should be used with caution when assessing differential diagnosis of FH 1

Plaque Instability and Recurrent Infarction

Young patients with MI demonstrate less extensive coronary atherosclerosis with higher prevalence of single-vessel disease, yet long-term prognosis is not benign, particularly in the setting of recurrent events on healed infarcts. 5

Mechanisms of Plaque Vulnerability in Young Patients

• Young FH patients have higher prevalence of lipid disorders, smoking, and family history of premature CAD compared to older MI patients, creating a milieu for unstable plaque formation 5
• The combination of genetic hypercholesterolemia, smoking history, and lifestyle factors plays a synergistic role in determining phenotype and plaque instability in premature MI 3
• Smoking history, obesity, and family history of premature CHD are independent risk factors for premature MI beyond genetic contributions 3

Risk of Reinfarction

• Patients with FH have lifetime exposure to elevated LDL-cholesterol, leading to progressive atherosclerotic burden that continues to accumulate even after initial MI 1, 7
• Underdiagnosis and undertreatment of FH remain major problems, with only one FH patient achieving LDL-cholesterol <2.5 mmol/L and none achieving <1.8 mmol/L in recent premature MI cohorts 2
• Low HDL-cholesterol is a key risk factor for recurrent ASCVD events in FH patients 1

Differential Diagnoses of MI at Age 25

Atherosclerotic Causes

• Familial hypercholesterolemia (monogenic LDLR, APOB, PCSK9, LDLRAP1 mutations) represents the most common genetic cause 1, 2
• Polygenic hypercholesterolemia mimicking FH phenotype but without identifiable monogenic mutation 4
• Elevated lipoprotein(a) as an independent causal factor, particularly when combined with other risk factors 6, 9
• Premature atherosclerosis due to smoking and drug use (cocaine, methamphetamine) 4, 5

Non-Atherosclerotic Causes (Critical to Exclude)

Myocardial infarction with nonobstructive coronary arteries (MINOCA) occurs in 10-20% of young patients with acute MI and requires different diagnostic and therapeutic approaches. 5

• Spontaneous coronary artery dissection (SCAD) is a frequent pathogenetic mechanism of AMI among young women, requiring high suspicion especially in the peripartum period 5
• Coronary vasospasm (Prinzmetal angina)
• Coronary embolism from atrial fibrillation, endocarditis, or paradoxical embolism
• Coronary thrombosis in hypercoagulable states (antiphospholipid syndrome, protein C/S deficiency)
• Takotsubo cardiomyopathy mimicking MI
• Myocarditis with troponin elevation

Key Diagnostic Distinction

• Intravascular imaging (IVUS, OCT) and cardiac magnetic resonance imaging are key for diagnosing MINOCA and differentiating from atherosclerotic MI 5

Emerging Diagnostic and Early Detection Strategies

Genetic Screening (Highest Priority for Early Detection)

Genetic testing is the most accurate way to diagnose FH and should be performed in all suspected cases to confirm diagnosis, enable cascade testing of family members, and guide treatment decisions. 1

• Comprehensive genetic testing should focus on the three most common causative genes: LDLR, APOB, and PCSK9 1
• After identifying a pathogenic variant in the proband, cascade genetic testing for the specific variant should be offered to all first-degree relatives, then second-degree and third-degree relatives as needed 1, 7
• Pre-test and post-test genetic counseling should be provided to all patients and at-risk relatives as an integral component of testing 1, 7
• Genetic testing enables identification of affected family members through cascade testing, which is highly cost-effective 1

Clinical Diagnostic Criteria

• The Dutch Lipid Clinic Network (DLCN) and Simon Broome criteria are the most widely used clinical diagnostic methods in adults, incorporating LDL-cholesterol levels, family history of premature CAD, and physical stigmata such as tendon xanthomas 1, 7
• LDL-cholesterol ≥190 mg/dL (≥4.9 mmol/L) in adults without secondary causes strongly suggests FH and warrants phenotypic screening of first-degree relatives 7
• In children, diagnosis relies on elevated LDL-cholesterol plus positive family history of premature coronary disease or high LDL-cholesterol in at least one parent 1, 7

Novel Biomarkers

Lipoprotein(a) measurement is now recommended for risk stratification in patients with intermediate-high ASCVD risk, FH, family history of early ASCVD, and progressive disease despite optimal therapy. 6, 10, 9

• Lp(a) serves as a risk modifier in the 2025 ESC guidelines, with elevated levels (>50 mg/dL) reclassifying patients to higher risk categories 10
• Highly sensitive C-reactive protein (hs-CRP) has been introduced as a risk modifier in the 2025 ESC guidelines for improved risk stratification 10
• Standardized laboratory measurement of Lp(a) is now available, though interpretation requires understanding of race/ethnic variation in expression 9

Coronary Artery Calcium (CAC) Scoring

CAC scoring improves risk estimation beyond traditional risk factor assessment and informs medication allocation and LDL-cholesterol goals, particularly in asymptomatic adults with FH. 12, 11

• The landmark CARDIA study (JAMA Cardiology 2017) demonstrated that CAC in adults aged 32-46 years associates with incident coronary heart disease and death 12
• CAC improves risk estimation to inform medication allocation and LDL-cholesterol goals beyond traditional risk factor risk estimation 11
• CAC scoring is useful in initial risk assessment but should not be used to monitor treatment effectiveness 1
• In very-high risk patients with high CAC burden, treatment to LDL-cholesterol values as low as <30 mg/dL further reduces ASCVD risk without significant adverse events 11

Coronary CT Angiography (CCTA)

• CCTA should be considered in asymptomatic adults with heterozygous FH to document presence and severity of subclinical atherosclerosis 1, 7
• CCTA every 5 years or less if clinically indicated is recommended for homozygous FH patients 1
• CCTA is particularly valuable for detecting non-obstructive coronary disease and differentiating atherosclerotic from non-atherosclerotic causes of MI 5

Cardiac Magnetic Resonance Imaging (CMR)

• CMR is key for diagnosing MINOCA and differentiating myocarditis, Takotsubo cardiomyopathy, and other non-atherosclerotic causes from atherosclerotic MI 5
• CMR can detect myocardial fibrosis and scar from prior infarction, relevant for the case of acute MI on healed infarct 5

Intravascular Imaging (IVUS/OCT)

• Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are key for diagnosing MINOCA, particularly SCAD, and assessing plaque characteristics in young patients 5

PET Imaging

• PET imaging can assess vascular inflammation and metabolic activity in atherosclerotic plaques, though its role in routine clinical practice for young MI patients remains investigational 1

Carotid Ultrasonography

• Carotid ultrasonography can be used to assess presence and severity of subclinical atherosclerosis in FH patients 1, 7

Doppler Echocardiography

• Doppler echocardiographic evaluation of the heart and aorta should be performed annually in homozygous FH patients to assess for aortic stenosis and supravalvular disease 1

Key Landmark Studies (Last 10-15 Years)

Genetic and Epidemiologic Studies

• CARDIA Study (JAMA Cardiology 2017): Demonstrated association of CAC in adults aged 32-46 years with incident CHD and death, establishing CAC as a valuable tool for risk assessment in young adults 12
• Chinese Premature MI Cohorts (Clinical Cardiology 2019, Lipids in Health and Disease 2019): Identified 4.4-7.6% prevalence of genetically confirmed FH in premature MI patients, with novel LDLR and LDLRAP1 mutations discovered 2, 3

Therapeutic Advances

• FOURIER and ODYSSEY OUTCOMES trials (referenced in 2019 AHA/ACC guidelines): Established efficacy of PCSK9 inhibitors for LDL-cholesterol reduction and cardiovascular event reduction 12
• GAUSS-3 and ODYSSEY ALTERNATIVE trials (JAMA 2016, Journal of Clinical Lipidology 2015): Demonstrated efficacy and tolerability of evolocumab and alirocumab in statin-intolerant patients 12
• Phase 2 trial of IONIS-APO(a)-LRX (Cardiovascular Drugs and Therapy 2019): Showed antisense oligonucleotide against LPA mRNA could specifically reduce Lp(a) by 90% with good tolerance, representing a promising future therapy 6

Risk Assessment Updates

• 2025 ESC/EAS Dyslipidemia Guidelines (Herz 2025): Introduced SCORE2 and SCORE2-OP for improved risk stratification, incorporated risk modifiers including Lp(a) and hs-CRP, and emphasized immediate high-intensity statin plus ezetimibe in acute coronary syndrome 10
• PREVENT Equations (American Journal of Preventive Cardiology 2026): New risk estimation equations with lower risk thresholds compared to prior Pooled Cohort Equations, improving primary prevention risk assessment 11

Management Implications for Very Young Adults

Immediate Treatment Approach

All genetically or phenotypically diagnosed FH patients require aggressive cholesterol-lowering therapy regardless of baseline LDL-cholesterol levels or absence of clinical stigmata, with high-intensity statin therapy initiated immediately upon diagnosis. 8, 7

• High-intensity statin therapy (rosuvastatin 20-40 mg or atorvastatin 40-80 mg) should be initiated immediately upon diagnosis in adults 7
• The 2025 ESC guidelines recommend immediate initiation of high-intensity statin treatment, mostly in combination with ezetimibe, in acute coronary syndrome 10
• Target LDL-cholesterol <100 mg/dL in patients without ASCVD or major risk factors, with minimum 50% reduction from baseline 7
• Target LDL-cholesterol <70 mg/dL for patients with imaging evidence of ASCVD or major risk factors 7
• Treatment escalation to ezetimibe and PCSK9 inhibitors is warranted when LDL-cholesterol remains elevated despite maximal statin therapy 8, 7

Secondary Prevention After MI

• Smoking cessation is by far the most effective secondary preventive measure in young patients with MI 5
• For very-high risk patients (such as a 25-year-old with recurrent MI on healed infarct), treatment to LDL-cholesterol values as low as <30 mg/dL further reduces ASCVD risk without significant adverse events 11
• Patients with elevated Lp(a) should be prioritized for PCSK9 inhibitor therapy until direct Lp(a)-lowering agents become available 11, 9

Critical Pitfalls to Avoid

• Do not delay pharmacotherapy in favor of lifestyle modifications alone, as FH patients have lifetime exposure to elevated LDL-cholesterol from birth, making early aggressive treatment essential 7
• Do not use general population risk calculators in FH patients, as these significantly underestimate cardiovascular risk 7
• Do not underestimate the importance of early intervention, as studies show earlier treatment leads to greater reduction in ASCVD events 1
• Do not overlook non-atherosclerotic causes (SCAD, vasospasm, thrombosis) in very young patients, as MINOCA occurs in 10-20% of young MI cases and requires different management 5
• Do not fail to screen family members after identifying FH in a young MI patient, as cascade testing is highly cost-effective and can prevent future events in relatives 1, 7